



## Supplementary Information

# A highly active chimeric lysin with a calcium-enhanced bactericidal activity against *Staphylococcus aureus* in vitro and in vivo

Xiaohong Li <sup>1,2§</sup>, Shujuan Wang <sup>1,2§</sup>, Raphael Nyaruaba <sup>1,2</sup>, Huan Liu <sup>1,2</sup>, Hang Yang <sup>1,2\*</sup>, and Hongping Wei <sup>1,2\*</sup>

**Table S1.** Bacterial strains used in this study.

Strain	Description
BL21(DE3)	F <sup>-</sup> <i>ompT hsdS<sub>B</sub>(r<sub>B</sub><sup>-</sup>m<sub>B</sub><sup>-</sup>) gal dcm λDE3</i> (harboring gene 1 of the RNA polymerase from the phage T7 under the <i>PlacUV5</i> promoter)
<i>E. coli</i> BL21/pET28a-ClyC	Constructed in this study
<i>E. coli</i> BL21/pET28a-Ply187CD	pET28a derivative carrying the catalytic domain of Ply187 gene
<i>E. coli</i> BL21/pET28a-SA97CBD	pET28a derivative containing the cell-wall binding domain of LysSA97 gene


**Table S2:** Primers used in the overlap PCR.

Code	Name	Sequence
A	Ply187CD-F	ATATCCATGGCATGGCACTGCCTAAACGGG
B	Ply187CD-R	AGTTCCAGGTGATCTTGTCCGCTGGTGGTG-TAGGTTTCGGTTC
C	SA97CBD-F	GAACCGAAACCTACACCACCGAGCGGACAAGATACTG-GAACT
D	SA97CBD-R	TATACTCGAGCGCCCATTGATGGTGCCAG


**Table S3.** MIC of ClyC against different *S. aureus* strains.

S. aureus strains	Drug resistance	MIC of ClyC (μg/mL)
WHS11016	Methicillin-resistant	18
WHS11095	Methicillin-resistant	18
WHS11048	Methicillin-resistant	18
WHS11101	Methicillin-resistant	18
WHS11044	Methicillin-resistant	18
WHS11051	Methicillin-resistant	18
WHS11036	Methicillin-resistant	9
WHS11098	Methicillin-resistant	18
WHS11034	Methicillin-resistant	18
WHS11009	Methicillin-resistant	9
WHS11040	Methicillin-resistant	9
AB91118	Methicillin-sensitive	9

N315	Methicillin-resistant	18
WHS11024	Methicillin-sensitive	4.5
WHS11041	Methicillin-resistant	18
WHS11011	Methicillin-resistant	9
WHS11018	Methicillin-resistant	18
WHS11032	Methicillin-resistant	18
WHS11005	Methicillin-resistant	18
WHS11099	Methicillin-resistant	9
WHS11046	Methicillin-resistant	36
WHS11100	Methicillin-resistant	18
WHS11026	Methicillin-resistant	18
WHS11037	Methicillin-resistant	9
WHS11033	Methicillin-resistant	18
WHS11025	Methicillin-resistant	18
ATCC29213	Methicillin-sensitive	18
WHS11102	Methicillin-resistant	36
WHS11017	Methicillin-resistant	18

**Figure S1.** Lytic spectrum of ClyC.

**Fig S1.** Susceptibility of ClyC to staphylococcus and single strains of *S. pyogenes*, *S. agalactiae*, *S. pneumoniae*, and *Listeria monocytogenes*. Strains were washed once with PBS and resuspended to a final  $\text{OD}_{600}$  of 0.8~0.9. After treatment with 25  $\mu\text{g}/\text{mL}$  of ClyC at 37 °C for 10 min, the final  $\text{OD}_{600}$  value of treated wells were subtracted from the PBS-treated well to yield the net change in  $\text{OD}_{600}$ , and the bactericidal efficiency determined by the value change of  $\text{OD}_{600}$ . The experiment was repeated three times. Error bars represent the standard deviations.

**Figure S2.** Cytotoxicity of ClyC.

**Fig S2.** Cytotoxicity of ClyC. (A) Cytotoxicity of ClyC to CHO-K1 cells. Cells were co-cultured with different concentrations of ClyC (0, 15.625, 31.25, 62.5, 125, 250, and 500  $\mu\text{g/mL}$ ) for 24 h and the relative viability was calculated by the change of OD<sub>570</sub> by MTT assay. (B) Concentration of IL-8 in mice serum at different times post ClyC treatment.